A phase I study of MAT2501 for the treatment of for the treatment of non-tuberculous mycobacteria (NTM) infections

Trial Profile

A phase I study of MAT2501 for the treatment of for the treatment of non-tuberculous mycobacteria (NTM) infections

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Amikacin (Primary)
  • Indications Gram-negative infections; Mycobacterial infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Mar 2017 Topline results published in a Matinas BioPharma media release.
    • 27 Mar 2017 Status changed from recruiting to completed, according to a Matinas BioPharma media release.
    • 08 Mar 2017 According to a Matinas BioPharma media release, top line results from this trial will be reported in the coming weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top